An observational study in Drug Resistant Epilepsy and Refractory Epilepsy, sponsored by NeuroOne Medical Technologies Corporation. Recruiting at 3 sites in United States. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by NeuroOne Medical Technologies Corporation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Drug Resistant Epilepsy with a site in United States — 29 open to participants now, 34 under way, 2 of them phase 3. Drug Resistant Epilepsy · United States.
Among the 78 studies in Drug Resistant Epilepsy with a site in United States, this one is one of 7 that started in 2026, is one of 7 observational ones, reaches primary completion later than 22 of the 33 other live ones, and was the 72nd registered.
258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.
Browse Drug Resistant Epilepsy studies →29 of the 78 studies in Drug Resistant Epilepsy with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18–70
Duke University · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 3–25
Mayo Clinic · Sites in United States
Ages 18–75
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 17 · Phase 3 7 · Phase 4 2
First in 2001; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 86 across 45 observational studies indexed under Drug Resistant Epilepsy.
Median enrollment 27 across the 67 interventional studies, 100 across the 7 observational. Of the 34 that completed or were terminated, 14 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 78 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with NeuroOne Medical Technologies Corporation as lead sponsor.
NeuroOne Medical Technologies Corporation has 1 study filed under Drug Resistant Epilepsy — fewer than ten, so there is no comparison to draw.
13 of the studies in Drug Resistant Epilepsy with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT06443463Biohaven Therapeutics Ltd.Long-term Safety and Tolerability of BHV-7000 | 2026-12 |
| NCT06425029Dartmouth-Hitchcock Medical CenterSelf-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application | 2026-12 |
| NCT06138808Duke University5-SENSE Score Validation Study | 2027-01 |
| NCT05273970University of ArizonaElectrochemical and Electrophysiological Study | 2027-02 |
Add all 13 to your calendar (.ics) → With an account.
Among the 78 studies in Drug Resistant Epilepsy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-site registry study that aims to collect real-world clinical outcomes and device performance of the OneRF Ablation System. The study focuses on patients with refractory epilepsy who undergo, or are being considered for, sEEG-guided RF ablation using the OneRF Ablation System, as part of routine seizure diagnosis and treatment.
Stereoelectroencephalography (SEEG) -guided radiofrequency (RF) ablation is a minimally invasive procedure that uses thin electrodes already placed in the brain for seizure diagnosis to deliver targeted heat to destroy brain tissue associated with epileptic seizures.
The OneRF Ablation System is a device cleared by the FDA in 2023 for this treatment. Since receiving FDA clearance, the OneRF Ablation System has been used in ablation procedures in patients with seizures at multiple hospitals. Early published clinical data show a meaningful decrease in seizure burden (1). One of the key features of the device is the ability to monitor and control temperature throughout the treatment. While the advantages of real-time temperature monitoring and control are increasingly being recognized, additional clinical information would be beneficial to understand the full impact of this technology on patient outcomes.
This study is a prospective and retrospective, multicenter, observational registry. The study will take place at up to 10 sites across the United States and is expected to enroll up to 100 participants, including both adults and children. The goal of the registry is to evaluate clinical outcomes and device performance of the OneRF Ablation System.
The study will include data collection from patients with drug resistant epilepsy who are undergoing sEEG evaluation for seizure diagnosis and treatment, and:
Data will be collected from patients before and throughout routine follow-up visits for up to one year after the RF ablation procedure. The study will look at seizure control, quality of life, adverse events, how the procedure is performed, and factors that may predict which patients benefit most.
Taking part in this registry does not change a patient's medical care. The study only collects information from treatments and follow-up visits that are already part of routine practice care for seizure management.
Patients diagnosed with drug resistant epilepsy (DRE)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Any condition that, in the judgement of the clinician, would make the participant inappropriate for registry participation
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This registry collects both retrospective data from patients diagnosed with drug resistant epilepsy (DRE) who previously underwent a RF ablation procedure and prospective data from DRE patients who are considered for a RF ablation procedure using the OneRF Ablation System.
Other: Participants are not assigned an intervention as part of the study.
For observational studies, participants are not assigned an intervention as part of the study.
Evaluate seizure outcomes
Percentage of seizure-free patients and responders (seizure reduction \>50%) at longitudinal time points
Time frame: baseline to up to one (1) year
Evaluate changes in seizure frequency
Change is seizure frequency at longitudinal time points
Time frame: baseline to up to one (1) year
Evaluate changes in seizure severity
Change is seizure severity at longitudinal time points
Time frame: baseline to up to one (1) year
Evaluate antiseizure medication
Changes in the antiseizure medication (ASM) dosage
Time frame: baseline to up to one (1) year
Gather product deficiency and patient safety events
Number and description of adverse events related to the device, user, RF ablation procedure, therapy, and others
Time frame: From enrollment through the completion of follow-up visits (approximately a one-year period)
Evaluate seizure related hospitalizations
Changes in seizure related emergency department visits and hospitalizations
Time frame: baseline to up to one (1) year
Evaluate device use
Questionnaire to assess clinician satisfaction with the device
Time frame: During the ablation procedure
RF ablation parameters
Collect RF ablation parameters (temperature and time) used for treatment
Time frame: During RF ablation procedure
RF ablation lesion characterization
Measurement of RF ablation lesion size from MRI
Time frame: From enrollment through the completion of follow-up visits (approximately a one-year period)
Evaluate patient selection for RF ablation
Tabulate RF ablation parameters, lesion size and seizure outcomes for each participant
Time frame: From ablation through the completion of follow-up visits (approximately a one-year period)
Evaluate health care resource utilization
Location of the procedure: operating room or epilepsy monitoring unit
Time frame: During the ablation procedure
Evaluate health care resource utilization
Personnel required for procedure
Time frame: During the ablation procedure
Evaluate health care resource utilization
Total cost of index procedure and follow-up cate, if permissible
Time frame: From enrollment through the completion of follow-up visits (approximately a one-year period)
Plan to share: No
Started Sep 2026 (actual). Primary completion is estimated for Jul 2028, 22 months after the start.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Oct 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.